Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
Open Access
- 12 July 2016
- journal article
- review article
- Published by Springer Nature in Pituitary
- Vol. 19 (5) , 536-543
Abstract
Purpose Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension. Pasireotide is a new-generation, multireceptor-targeted somatostatin receptor ligand approved for CD (subcutaneous [SC] injection formulation) and acromegaly (long-acting release [LAR] formulation). In clinical studies of pasireotide, hyperglycemia-related adverse events (AEs) were frequently observed. This review highlights differences in reported rates of hyperglycemia in pasireotide trials and discusses risk factors for and management of pasireotide-associated hyperglycemia. Methods Clinical trials evaluating pasireotide in patients with CD or acromegaly were reviewed. Results The frequency of hyperglycemia-related AEs was lower in patients with acromegaly treated with pasireotide LAR (57.3–67.0 %) than in patients with CD treated with pasireotide SC (68.4–73.0 %). Fewer patients with acromegaly treated with pasireotide LAR discontinued therapy because of hyperglycemia-related AEs (Colao et al. in J Clin Endocrinol Metab 99(3):791–799, 2014, 3.4 %; Gadelha et al. in Lancet Diabetes Endocrinol 2(11):875–884, 2014, 4.0 %) than did patients with CD treated with pasireotide SC (Boscaro et al. in Pituitary 17(4):320–326, 2014, 5.3 %; Colao et al. in N Engl J Med 366(10):914–924, 2012, 6.0 %). Hyperglycemia-related AEs occurred in 40.0 % of patients with acromegaly treated with pasireotide SC, and 10.0 % discontinued treatment because of hyperglycemia. Ongoing studies evaluating pasireotide LAR in patients with CD and management of pasireotide-induced hyperglycemia in patients with CD or acromegaly (ClinicalTrials.gov identifiers NCT01374906 and NCT02060383, respectively) will address these key safety issues. Conclusions Disease pathophysiology, drug formulation, and physician experience potentially influence the differences in reported rates of pasireotide-induced hyperglycemia in CD and acromegaly. Hyperglycemic effects associated with pasireotide have a predictable pattern, can be managed with antidiabetic agents, and are reversible upon discontinuation.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 39 references indexed in Scilit:
- Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II studyPituitary, 2013
- Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III studyEndocrine Abstracts, 2013
- Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension studyPituitary, 2013
- Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotideDiabetes & Metabolism, 2013
- Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature reviewPituitary, 2012
- A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteersDrug Design, Development and Therapy, 2012
- A 12-Month Phase 3 Study of Pasireotide in Cushing's DiseaseNew England Journal of Medicine, 2012
- Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomasBMC Endocrine Disorders, 2010
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus StatementThe Journal of Clinical Endocrinology & Metabolism, 2008
- Insulin secretion is inhibited by subtype five somatostatin receptor in the mouseSurgery, 1998